CNSide Assay Data Showcases Biomarker Insights For Leptomeningeal Metastases At Society for NeuroOncology 2024

CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, Inc., will showcase data highlighting the effectiveness of the CNSide CSF Assay Platform in detecting key biomarker mutations in cerebrospinal fluid (CSF) and their role in guiding treatment decisions for leptomeningeal metastases (LM). This research will be presented at the 2024 Society for NeuroOncology (SNO) Annual Meeting from November 21-24 in Houston, Texas.

Marc H. Hedrick, M.D., Plus Therapeutics’ President and Chief Executive Officer, said in a statement, “The data from CNSide suggests that biomarker mutation profiles in LM are dynamic, offering valuable insights for treatment strategies. The genetic drift observed in LM suggests an important role for radiotherapeutics such as Rhenium (186Re) Obisbemeda in addressing this challenging disease.”

Key Insights:

• The CNSide CSF Assay analysed 258 CSF samples from 66 LM patients, focusing on clinically significant biomarkers.

• Fourteen biomarkers were assessed using fluorescent in situ hybridisation (FISH) for 11 biomarkers and immunocytochemistry (ICC) for three. Of these, 12 biomarkers showed treatment-related changes.

• The FISH analysis identified biomarker changes in 88% (58/66) of patients, uncovering 26 new actionable biomarkers.

• ICC analysis detected changes in 20% (13/66) of patients, revealing seven new actionable biomarkers.

Dr. Arushi Tripathy, M.D, from the University of Michigan’s Department of Neurosurgery will present the research data on Friday, November 22, at 7:30 p.m. CST in a session titled “The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CSF-TCs) Reveals Implications for Differential Treatment of the LMD Tumor.”